4D Molecular Therapeutics FDMT US — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's us — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's US — revenue?
- 4D Molecular Therapeutics (FDMT) reported US — revenue of $90K in Q1 2026.
- How has 4D Molecular Therapeutics's US — revenue changed year-over-year?
- 4D Molecular Therapeutics's US — revenue increased by 542.9% year-over-year, from $14K to $90K.
- What is the long-term trend for 4D Molecular Therapeutics's US — revenue?
- Over 3 years (2021 to 2024), 4D Molecular Therapeutics's US — revenue has grown at a -32.4% compound annual growth rate (CAGR), from $120K to $37K.
- What does US — revenue mean?
- This metric represents the total gross income generated from operations within the United States geographic segment. It reflects the company's ability to commercialize its therapeutic product candidates and secure regional partnerships or licensing agreements within this specific market. Tracking this figure helps investors assess the geographic concentration of revenue and the success of market penetration strategies for the company's gene therapy portfolio.